TriNetX bolsters clinical research network with Custodix buy, quadruples European staff

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/carloscastilla)
(Image: Getty/carloscastilla)

Related tags TriNetX Clinical research Data

TriNetX acquires Belgium-based Custodix NV to support industry partners looking to collaborate with non-US hospitals – becoming a “one-stop-shop” for clinical data, says SVP.

The global health research network TriNetX today announced its acquisition of Belgium-based Custodix NV and its InSite network, which operate in 12 countries throughout Europe.

Custodix NV provides clinical trial design, patient feasibility and recruitment services. The company’s InSite platform was developed as part of the Innovative Medicines Initiative (IMI​) research program in collaboration with the pharmaceutical industry through the EHR4CR​ project.

As per the acquisition – financial details of which were not disclosed – Custodix becomes a division ofTriNetX and will under the name InSite, aTriNetX company. The deal quadruples the size of TriNetX's current European staff and establishes an EU headquarters in Belgium.

Additionally, Custodix CEO Brecht Claerhout will now serve as senior vice president and managing director of InSite and Europe. 

“Our industry partners are conducting research on a global scale and looking to collaborate with non-US hospitals. Given TriNetX’s momentum, we felt the fastest way to create a ‘one-stop shop’ for clinical data, was to unite with the leading European research network, InSite,” ​said TriNetX​ SVP of Corporate Development Maulik Mehta.

“This lead to our acquisition of Custodix NV,”​ he told us. “For Custodix, they wanted to be able to offer their hospital community more clinical trials and together we look forward to rolling out new functionality across the networks.”

As for how the companies will be integrated, Mehta said the vision is to create “one experience”​ for its customers.

“We are working quickly to integrate the two networks on to a single self-service platform. In the short term, InSite’s hospital community can expect more clinical trials and in the medium term, access to more functionality,”​ he explained. “Throughout this, InSite remains the local European research network and the values, company contacts and offerings remain unchanged.”

TriNetX last month closed a Series D financing round​, bringing total funding to $102m as the network continues to expand globally. The company’s customer base currently includes 29 industry partners, including Novartis, Sanofi​ and Pfizer​, and the contract research organizations (CROs) Syneos and Icon​.

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Related suppliers

Follow us


View more